

DHMEQ, a novel NF- κ B inhibitor, enhances anti-tumor activity of taxanes in anaplastic thyroid cancer cells

Zhaowei MENG^{1, 2}, Norisato MITSUTAKE², Masahiro NAKASHIMA³, Dmytro STARENKI^{2, 7}, Michiko MATSUSE², Shu TAKAKURA², Hiroyuki NAMBA², Vladimir SAENKO⁴, Kazuo UMEZAWA⁶, Akira OHTSURU⁵ and Shunichi YAMASHITA^{2, 4, 5}

¹Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China; ²Department of Molecular Medicine, ³Tissue and Histopathology Section, Division of Scientific Data Registry, ⁴Department of International Health and Radiation Research, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; ⁵Takashi Nagai Memorial International Hibakusha Medical Center, Nagasaki University Hospital, Nagasaki, Japan; ⁶Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Kanagawa, Japan, ⁷The Research Institute of Personalized Health Sciences, Health Science University of Hokkaido, Hokkaido, Japan.

Running title: Combination of DHMEQ and Taxanes in ATC

Key words: DHMEQ, NF- κ B, paclitaxel, docetaxel, anaplastic thyroid cancer

Correspondence: Norisato Mitsutake, MD PhD
Department of Molecular Medicine, Atomic Bomb Disease Institute,
Nagasaki University Graduate School of Biomedical Sciences
1-12-4 Sakamoto, Nagasaki 852-8523, Japan
Tel: +81 (95) 819-7116, Fax: +81 (95) 819-7117
E-mail: mitsu@nagasaki-u.ac.jp

DISCLOSURE STATEMENT: The authors have nothing to disclose.

This work was supported in part by Grant-in-Aid for Scientific Research (#18790637, #19390253 and #20790461) and Global COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Abstract

Nuclear factor κ B (NF- κ B), as an anti-apoptotic factor, crucially affects the outcomes of cancer treatments, being one of the major culprits of resistance to chemotherapy. In this study, we investigated whether DHMEQ, a novel NF- κ B inhibitor, can enhance anti-tumor activities of taxanes in anaplastic thyroid cancer (ATC) cells. Taxanes induced NF- κ B activation in ATC cells, which could compromise the therapeutic effect of the drugs. However, DHMEQ, by inhibiting the nuclear translocation of NF- κ B, completely suppressed the DNA binding capacities of NF- κ B and lowered the levels of nuclear NF- κ B protein. Compared to single treatment (either taxane or DHMEQ), the combined treatment strongly potentiated apoptosis, confirmed by cell survival assay, Western blotting for PARP, caspase 3, XIAP and survivin, and flow cytometry for annexin V. Furthermore, we also demonstrate for the first time that the combined treatment showed significantly greater inhibitory effect on tumor growth in nude mice xenograft model. These findings suggest that taxanes are able to induce NF- κ B activation in ATC cells, which could attenuate anti-tumor activities of the drugs, but inhibition of NF- κ B by DHMEQ creates a chemo-sensitive environment and greatly enhances apoptosis in taxanes-treated ATC cells *in vitro* and *in vivo*. Thus, DHMEQ may emerge as an attractive therapeutic strategy to enhance the response to taxanes in ATCs.

Introduction

Nuclear factor κ B (NF- κ B), named because it was first found to be a nucleoprotein able to bind to the enhancer region of the immunoglobulin κ light chain gene, controls the expression of numerous gene products that play crucial roles in cell survival, angiogenesis and carcinogenesis. In normal cells NF- κ B is strictly regulated, whereas in cancer cells it is often constitutively activated to high level (1). More importantly, NF- κ B activation in cancer cells has been proven in many studies to be one of the major culprits of resistance to chemotherapy (2, 3). NF- κ B is typically a heterodimeric complex composed of Rel family proteins p50 and p65. It usually resides in the cytoplasm in an inactive form due to its association with its inhibitor I κ B. A number of extracellular signals can lead to NF- κ B activation through the phosphorylation and degradation of I κ B. Then liberated NF- κ B translocates to the nucleus, binds to specific promoters and regulates target gene expression.

Taxanes (including docetaxel and paclitaxel) break the equilibrium of microtubule polymerization by preventing tubulin depolymerization during mitosis, thus impairing cell proliferation in tumors. Taxanes have been used for several malignant tumors in clinic. As no effective systemic treatment has been

established for anaplastic thyroid cancer (ATC), taxanes could be a promising candidate. In fact, paclitaxel has been confirmed to be effective in ATC cells *in vitro* (4). However, it has been reported that taxanes also induce NF- κ B activation in different types of malignant cells (5-10). Along with other reasons of intrinsic or acquired chemotherapy resistance to taxanes, such as β -tubulin mutations, different β -tubulin isotypes or multidrug resistance gene expression, this taxanes-induced NF- κ B activation also attenuates anti-tumor effect of the drugs and contributes to chemotherapy resistance (11).

NF- κ B inhibitors have been considered as an appealing and target-oriented approach to deal with the chemoresistant issue. A number of NF- κ B inhibitors have been reported to be effective. Most of them, including curcumin (5, 12), genistein (13-15), parthenolide (16-18), BAY 11-7085 (9) and PS-1145 (6), act as I κ B kinase (IKK) inhibitors. Dehydroxymethylepoxyquinomicin (DHMEQ), a NF- κ B inhibitor designed from the structure of an antibiotic epoxyquinomicin C, inhibits NF- κ B nuclear translocation (19, 20) as well as SN50 (21). It has been shown that DHMEQ is non-toxic and effective for ATC cells both *in vitro* and *in vivo* (22). As pointed out, DHMEQ inhibits NF- κ B activity and up-regulates proapoptotic signaling in ATC cells, whereas

normal thyroid epithelium cells are relatively resistant to the drug (22).

To our knowledge, there has been no study investigating docetaxel effect on ATC cells using animal model. Docetaxel has been generally reported to be more effective and also less toxic than paclitaxel. Here we demonstrate that docetaxel is effective for ATC cells *in vitro* and *in vivo*. Furthermore, in a combined regimen, DHMEQ could greatly optimize the therapeutic effects of taxanes in ATC cells.

Materials and Methods

Reagents

Racemic DHMEQ was dissolved in dimethyl sulfoxide (DMSO) (Wako Chemicals, Osaka, Japan) at stock concentration of 10 mg/ml, and then stored at -20°C . Docetaxel and paclitaxel (Wako Chemicals) were dissolved in DMSO at stock concentration of 1 mM for *in vitro* experiments, and for *in vivo* experiments docetaxel was dissolved at 20 mg/ml. SN50 was purchased from Calbiochem (San Diego, CA). Antibodies were obtained from the following sources: anti-p50 polyclonal, p65 polyclonal, survivin polyclonal, and β -actin monoclonal from Santa Cruz Biotechnology (Santa Cruz, CA); anti-IkBa polyclonal, X-linked inhibitor of apoptosis (XIAP)

polyclonal, poly (ADP-ribose) polymerase (PARP) polyclonal, cleaved caspase 3 polyclonal, anti-rabbit IgG, and anti-mouse IgG horseradish peroxidase-conjugated secondary antibodies from Cell Signaling Technology (Beverly, MA).

Cell culture

Human ATC cell lines ARO and FRO were initially provided by Dr. James A. Fagin (University of Cincinnati, College of Medicine, Cincinnati, OH). KTC-2 cells were from Dr. Kurebayashi (Kawasaki Medical School, Kurashiki, Japan) (23). All cells were grown in RPMI 1640 (Sigma, St. Louis, MO) supplemented with 5% fetal bovine serum and 1% (w/v) penicillin/streptomycin (Sigma) in a 5% CO_2 humidified atmosphere at 37°C .

Cell survival assay

Cell suspensions (100 μL , 3000 cells/well) were added to each well of 96-well plate and incubated for 24 hours before treatment. Solutions containing various concentrations of taxanes and/or DHMEQ or SN50 were added to each well in 11 μL of medium, with 4 wells used for each concentration. In the control wells DMSO was added, and final concentration of DMSO in any well did not exceed 0.2%. After incubation, a water-soluble tetrazolium salt

(WST)-based assay was implemented as follows: first aspirated old medium, added 50 μ L of fresh RPMI 1640, and then added 5 μ L of CKK-8 solution (Dojindo, Osaka, Japan) to each well and incubated for 60 minutes at 37°C. Optical densities were measured at 450 nm in a microplate reader ImmunoMini NJ-2300 (System Instruments, Tokyo, Japan).

Preparation of cell extracts

For total cell extracts, adherent cells were washed twice with ice-cold PBS, scraped with a rubber policeman, collected in 1 ml PBS, and centrifuged for 3 minutes at 1000 rpm at 4°C. The pellet was then resuspended in 100 μ l of lysis buffer (20 mM Tris-HCl pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.5% Triton-X, 50 mM NaF, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate and 2 mM phenylmethylsulfonylfluoride) containing protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). After incubation for 20 minutes on ice, the lysate was centrifuged for 15 minutes at 14,000 rpm. The supernatant was stored at -80°C until use. Nuclear extracts were prepared according to the method of Andrews and Faller (24) with some modifications. In brief, attached cells were harvested, washed with ice-cold PBS, suspended in 400 μ L of buffer A (10 mM HEPES pH 7.9, 10 mM KCl,

1.5 mM MgCl₂, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonylfluoride and 0.1% Nonidet P-40) and incubated on ice for 20 minutes. Nuclei were pelleted by centrifugation for 5 minutes at 14,000 rpm, resuspended in 40 μ L of buffer C (20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl₂, 1 mM dithiothreitol, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonylfluoride and 20% glycerol), incubated on ice for 20 minutes and centrifuged for 15 minutes at 14,000 rpm at 4°C. The supernatant was also stored at -80°C. Protein concentrations were determined with a bicinchoninic acid assay reagent kit (Sigma).

DNA-binding assay

The multi-well colorimetric assay for active NF- κ B was performed as described previously (25, 26). Briefly, equal amount of nuclear extracts were incubated in 96-well plate coated with immobilized oligonucleotide containing a NF- κ B consensus binding site. NF- κ B binding to the target oligonucleotide was detected with primary antibody specific to p65 subunit and HRP-conjugated secondary antibody. For quantification of activity, optical densities were measured at 450 nm using a microplate reader ImmunoMini NJ-2300.

Western blotting

Equal amount of protein was separated by SDS-PAGE in 10% or 15% polyacrylamide gels. Proteins were transferred onto nitrocellulose membranes (Pall Corporation, MI) by semidry blotting. Membranes were blocked with Tris-buffered saline/0.1% Tween 20 (TBST) containing 1% nonfat dry milk for 60 minutes at room temperature. After washing three times with TBST, membranes were incubated with appropriately diluted primary antibodies at 4°C overnight. After washing three times with TBST, the blots were incubated with horseradish peroxidase-conjugated species-specific secondary antibody for 1 h at room temperature and then again washed three times. Then the complexes were visualized in a LAS-3000 imaging system (FUJIFILM, Tokyo, Japan) by using the enhanced chemiluminescence reagents (Nacalai Tesque, Kyoto, Japan).

Flow cytometry analysis with the annexin V/propidium iodide staining

Adherent cells were harvested by trypsinization, and 4×10^5 cells were double stained with FITC-conjugated annexin V and propidium iodide for 15 minutes at room temperature in a Ca^{2+} -enriched binding buffer (Apoptosis Detection Kit, Wako Chemicals) and then analyzed on a FACS Vantage SE System

flow cytometer (BD Biosciences, San Jose, CA). FITC and propidium iodide emissions were detected in FL-1 and FL-3 channels, respectively. Analysis was done with Cell Quest software (BD Biosciences).

In vivo xenograft model

All procedures involving animal experiments and their care in this study were conducted in accordance with the principles and procedures outlined in the Guide for the Care and Use of Laboratory Animals at Nagasaki University. FRO cells (5×10^6) resuspended in RPMI 1640 were injected s.c. into both flanks of 6 weeks old male BALB/c *nu/nu* mice (CLEA Japan, Tokyo, Japan), 6 animals per group. Then they were randomly assigned into four groups. The tumor sizes were measured each alternate day with calipers, and tumor volumes were calculated according to the formula $a^2 \times b \times 0.4$, where a is the smallest tumor diameter and b is the diameter perpendicular to a . DHMEQ, diluted in PBS/DMSO (ratio 1:1), was injected i.p. at a dose of 6 mg/kg/day for 14 days, beginning from day 5 after tumor implantation. Docetaxel, diluted in the same way, was injected i.p. at a dose of 5 mg/kg on day 5 and day 12. Combined treated mice were given both drugs. Control group mice received vehicle injections only. For two more weeks,

tumor size was monitored and body weight, feeding behavior, and motor activity of each animal were used as indicators of general health.

Statistical Analysis

All data were expressed as the mean \pm SD. Differences between groups were examined for statistical significance with one-way ANOVA followed by Tukey post test. *p* value not exceeding 0.05 was considered statistically significant.

Results

Cytotoxic effect of taxanes and/or DHMEQ on ATC cells

Since both paclitaxel and DHMEQ have been reported to have cytotoxic effects on ATC cells, while normal thyrocytes exhibit significantly lower sensitivity to them (4, 22), in the current experiment, we first determined the proper concentrations of the drugs to use. FRO and ARO cells were treated with different concentrations of docetaxel, paclitaxel and/or DHMEQ for 24 hours, and then cell survival assay was done. Survival rates of ATC cells showed inverse relationship to the dosage of any drug (Fig. 1). For *in vitro* experiments, concentrations of taxanes and DHMEQ were

determined as 4 nM and 10 μ g/ml, respectively. As shown in Fig. 1, the combined treatment strongly enhanced growth inhibitory effect compared to single treatment (Fig. 1).

Combined effects were also observed in cells with wild-type p53 or in cells treated with SN50

Since both ARO and FRO cells harboring *TP53* mutation, we used KTC-2 cells also derived from ATC but having no *TP53* mutation (our unpublished data) to check the effect of mutational status of *TP53*. As shown in Fig. 2, the combined treatment also showed significant enhancement compared to single treatment. We next used SN50, another NF- κ B inhibitor, to confirm the effect of combination. Although SN50 was shown to inhibit nuclear translocation of NF- κ B, NFAT and AP-1 at a high concentration (210 μ g/ml) (27), lower doses of SN50 (37.5 μ g/ml) selectively inhibited NF- κ B translocation (28). In both ARO and FRO cells, the combined treatment (docetaxel and SN50) similarly enhanced growth inhibition (Fig. 2), suggesting that inhibition of NF- κ B activation induces taxanes-sensitive environment in ATC cells. Note that the effect of SN50 was smaller than that of DHMEQ. This is probably due to prolonged JNK activation by DHMEQ,

whereas SN50 did not activate JNK signaling. We have reported this in a previous paper (22).

Effects of taxanes and DHMEQ on NF- κ B in ATC cells

To examine the effects of taxanes on NF- κ B signaling in ATC cells, we performed a DNA-binding assay using nuclear extracts from drug-treated FRO cells, which have already been reported to possess a high level of constitutively active NF- κ B (29). The cells were treated with docetaxel for 24 hours, during the time course the binding activity of nuclear p65 was gradually increased (Fig. 3A). However, if the cells were pretreated with DHMEQ for 1 hour and then exposed to docetaxel, the level of p65 was suppressed, especially during the first 8 hours (Fig. 3A). We also checked I κ B α expression after the treatment. Consistent with our previous data (22), DHMEQ treatment decreased I κ B α protein level. NF- κ B is known to bind the I κ B promoter and activates its synthesis, and therefore the inhibition of NF- κ B by DHMEQ probably suppressed *de novo* synthesis of I κ B α . Presumably, for the same reason, I κ B α expression after treatment with docetaxel was not dramatically reduced (Fig. 3B). On the other hand, nuclear p50 and p65 levels were clearly suppressed by DHMEQ treatment at 4 hours but recovered at 24 hours,

mostly consistent with the result of DNA-binding assay (Fig. 3A and B). The amount of nuclear p50 and p65 was slightly increased in paclitaxel as well as docetaxel group but decreased in DHMEQ and combination treatment groups in both ARO and FRO cells (Fig. 3C). These results confirmed not only the phenomenon of taxane-induced NF- κ B activation, but also that DHMEQ can inhibit the effect, just as DHMEQ has been reported to prevent unstimulated, TNF- α -induced or chemotherapeutic agent-induced accumulation of NF- κ B subunits in cancer cell lines (20, 22, 30-32).

Both taxanes and DHMEQ can induce apoptosis

Since cleavages of caspase 3 (a key executioner of apoptosis) and PARP (a main cleavage target of caspase 3) are characteristic indices of apoptosis, we examined their changes by Western blotting. After treatment with taxanes or DHMEQ for 24 hours, any agent induced cleavage of PARP (p89) and caspase 3 (p19 and p17) (Fig. 4A and B), consistent with previous reports (22, 33-36). The cleaved PARP and caspase 3 levels were further increased by the combined treatment, suggesting that more ATC cells underwent apoptosis (Fig. 4A and B). During the 24-hour time course of the treatment

with docetaxel, the level of cleaved PARP and caspase 3 was gradually and slowly increased up to 24 hour (Fig. 4C). On the other hand, pretreatment with DHMEQ for 1 hour caused both cleavages much earlier and even stronger (Fig. 4C).

Synergistic apoptosis detected by flow cytometry

To further confirm the effects of combined treatment on apoptosis, the cells were treated with the drugs for 16 hours and then double stained with FITC-conjugated annexin V and propidium iodide. While either drug slightly induced apoptosis, combined treatment synergistically increased apoptosis (Fig. 5).

Western blotting of anti-apoptotic factors

XIAP and survivin, belonging to the human inhibitors of apoptosis (IAP) family, are target genes regulated by NF- κ B, and they are overexpressed in many cancers (1, 37). We tested whether taxanes and/or DHMEQ modulate the expression of these antiapoptotic gene products. Besides high basal levels of XIAP and survivin in ATC cell lines, taxanes further increased their levels (Fig. 6). However, when treated with DHMEQ, their levels were markedly reduced to even less than basal level (Fig. 6). These data indicate that both

constitutive high levels and taxanes-induced XIAP and survivin expressions can be successfully suppressed by DHMEQ, consistent with our previous reports (4, 22) and papers from others (31, 38).

***In vivo* effects of the combined treatment with taxanes and DHMEQ**

To explore the effects of the combined treatment *in vivo*, we used animal xenograft model inoculated with FRO cells. As shown in Fig. 7, treatment with either drug was able to delay tumor growth, but the effect of the combined treatment with DHMEQ and docetaxel was far greater, with three locations (in two mice) remarkably having no apparent tumor. During the course of the therapy no changes in behavior and body weight were observed.

Discussion

Although taxanes have been shown to possess powerful cell-killing abilities in a variety of cancer cells including ATC (4), they have also been reported to induce NF- κ B activation in several types of malignant cells, including breast (5, 17, 18), ovarian (9, 12), prostate (13, 16), pancreatic (8, 14), gastric (7) and lung (39) cancers. The present data showed

that taxanes induced NF- κ B activation in ATC cells as well. NF- κ B activation mediates survival signals that counteract apoptosis, and could greatly compromise the therapeutic effect of taxanes. Adjuvant attempts to inhibit NF- κ B and increase the therapeutic efficacies of taxanes have been reported for all of the above mentioned cancer cell lines. However, there have been no reports regarding a NF- κ B inhibitor in an adjuvant setting with taxanes for ATC cells. We demonstrated in the current study that although taxanes induced NF- κ B activation in ATC cells, DHMEQ could effectively inhibit the translocation of NF- κ B, suppress anti-apoptotic factors, and greatly enhance apoptosis. We also showed for the first time that a combination of DHMEQ and docetaxel was much more effective in the inhibition of tumor growth than monotreatment in nude mice xenograft models.

As a selective NF- κ B inhibitor, DHMEQ is able to decrease transcription of many anti-apoptotic genes and then lower the threshold of triggering apoptosis. Therefore, when used in combination with subtoxic concentrations of chemotherapeutic drugs, DHMEQ could create a chemo-sensitizing environment in various cancers. This is especially beneficial for tumors with intrinsic or acquired drug resistance (3). Consistent with our

findings, several studies of applying DHMEQ in the armamentarium of anti-cancer therapeutics have been carried out, and synergistic effects were shown (32, 38, 40-42). Ruan et al. (40) used low concentrations of DHMEQ (1.0 or 5.0 μ g/mL) to enhance the sensitivity of two head and neck squamous cell carcinoma cell lines to cisplatin, and synergistic cytotoxic effects were observed. Poma et al. (32) used DHMEQ as a sensitizing agent in hepatic cancer. DHMEQ (5.0 μ g/mL) also exhibited synergy with cisplatin, decreasing the levels of pro-survival genes and IL-6 production. Horie et al. (41) used DHMEQ (5.0 μ g/mL) in combination with fludarabine to treat chronic lymphocytic leukemia. DHMEQ abrogated both constitutive and induced NF- κ B activities and enhanced fludarabine-induced apoptosis. Besides, the combination of DHMEQ (10 μ g/mL) and INF- γ has been reported to synergistically inhibit renal cancer cells' proliferation (38). Very recently, Jazirehi et al. (42) tested combinations of DHMEQ with several chemotherapeutic drugs in non-Hodgkin's lymphoma. The wild-type cells were pretreated with DHMEQ (10 μ g/mL), while the rituximab-resistant clones were pretreated with a higher concentration of DHMEQ (20 μ g/mL). All cells were then incubated with subtoxic concentrations of

paclitaxel, adriamycin, cisplatin, vincristine and etoposide and then subjected to DNA fragmentation assay to measure apoptosis. DHMEQ chemo-sensitized both types of cells, suggesting that DHMEQ successfully reversed the cells from chemo-resistant to chemo-sensitive.

Based on our and others' findings, we are led to propose a mechanistic scheme, as shown in Fig. 8, elucidating the enhanced induction of apoptosis by DHMEQ and taxanes. In ATC cells, dual effects of taxanes exist: they bind to microtubule, impair mitosis and induce apoptosis. However, at the same time, they can also induce NF- κ B activation, leading to cell survival. DHMEQ can block the nuclear translocation of NF- κ B and promote apoptosis. By this mechanism, DHMEQ can presumably modulate the balance between pro- and anti-apoptotic signals and enhance taxanes-induced apoptosis synergistically.

Collectively, we presented *in vitro* and for the first time *in vivo* evidences showing that DHMEQ could abrogate NF- κ B activation induced by the chemotherapeutic agent taxanes and create a more favorable pro-apoptotic environment, leading to enhancement of killing effect in the combined regimen. NF- κ B inhibitor SN50 also showed enhanced effects in combination with radiotherapy, perhaps through

the same mechanism (29). Thus, DHMEQ, as an effective NF- κ B inhibitor, could be applicable in several combination regimens.

In clinical practices, combined treatment is commonly considered to achieve better therapeutic outcome. However, sometimes it may cause adverse side-effects and systemic toxicities, which can be devastating for advanced-stage cancer patients. DHMEQ, being an antibiotic derivative, has very low side-effects as shown in many *in vivo* experiments (30, 33, 34, 43-47), and we also reported that normal thyroid epithelial cells are resistant to DHMEQ (22). Thus, as the combination decreases the dosage of taxanes, it can circumvent the unwanted toxicity of taxanes, and above all therapeutic effects increase. It would be promising that the molecular target-oriented co-administration of DHMEQ and taxanes will emerge as an attractive therapeutic strategy for ATC patients.

Acknowledgements

This work was supported in part by Grant-in-Aid for Scientific Research (#18790637, #19390253 and #20790461) and Global COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan

References

1. **Pacifico F, Leonardi A** 2006 NF-kappaB in solid tumors. *Biochem Pharmacol* 72:1142-1152
2. **Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr.** 1999 Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. *Nat Med* 5:412-417
3. **Katsman A, Umezawa K, Bonavida B** 2007 Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. *Drug Resist Updat* 10:1-12
4. **Pushkarev VM, Starenki DV, Saenko VA, Namba H, Kurebayashi J, Tronko MD, Yamashita S** 2004 Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. *Endocrinology* 145:3143-3152
5. **Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE** 2005 Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. *Clin Cancer Res* 11:7490-7498
6. **Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campas C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B** 2006 Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. *Clin Cancer Res* 12:5578-5586
7. **Nakahara C, Nakamura K, Yamanaka N, Baba E, Wada M, Matsunaga H, Noshiro H, Tanaka M, Morisaki T, Katano M** 2003 Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells. *Clin Cancer Res* 9:5409-5416
8. **Zhang H, Morisaki T, Nakahara C, Matsunaga H, Sato N, Nagumo F, Tadano J, Katano M** 2003 PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. *Oncogene* 22:2088-2096
9. **Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J,**

- Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y** 2004 Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. *Clin Cancer Res* 10:7645-7654
10. **Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ** 2002 The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. *Oncogene* 21:6510-6519
 11. **McGrogan BT, Gilmartin B, Carney DN, McCann A** 2007 Taxanes, microtubules and chemoresistant breast cancer. *Biochim Biophys Acta*
 12. **Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK** 2007 Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. *Clin Cancer Res* 13:3423-3430
 13. **Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH** 2006 Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. *Cancer Res* 66:4816-4825
 14. **Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar FH** 2004 Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. *Pancreas* 28:e90-95
 15. **Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH** 2005 Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. *Cancer Res* 65:6934-6942
 16. **Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW, Jr., Nakshatri H,**

- Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ** 2006 Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. *Prostate* 66:1498-1511
17. **Sweeney CJ, Mehrotra S, Sadaria MR, Kumar S, Shortle NH, Roman Y, Sheridan C, Campbell RA, Murry DJ, Badve S, Nakshatri H** 2005 The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. *Mol Cancer Ther* 4:1004-1012
18. **Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ, Jr., Sledge GW, Jr., Nakshatri H** 2000 Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. *Oncogene* 19:4159-4169
19. **Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S, Inoue J, Umezawa K** 2000 Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. *Bioorganic & medicinal chemistry letters* 10:865-869
20. **Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K** 2002 Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. *The Journal of biological chemistry* 277:24625-24630
21. **Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J** 1995 Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. *The Journal of biological chemistry* 270:14255-14258
22. **Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S** 2004 Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. *Clin Cancer Res* 10:6821-6829
23. **Kurebayashi J, Otsuki T, Tanaka K, Yamamoto Y, Moriya T, Sonoo H** 2003 Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid

- hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2. *Thyroid* 13:249-258
24. **Andrews NC, Faller DV** 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. *Nucleic Acids Res* 19:2499
 25. **Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S** 2006 BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. *Endocrinology* 147:5699-5707
 26. **Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, Remacle J** 2001 Development of a sensitive multi-well colorimetric assay for active NFkappaB. *Nucleic Acids Res* 29:E21
 27. **Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J** 1998 Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. *J Immunol* 161:6084-6092
 28. **Kolenko V, Bloom T, Rayman P, Bukowski R, Hsi E, Finke J** 1999 Inhibition of NF-kappa B activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. *J Immunol* 163:590-598
 29. **Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S** 2004 Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. *J Clin Endocrinol Metab* 89:410-418
 30. **Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K** 2005 Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. *Clin Cancer Res* 11:1287-1293
 31. **Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K** 2006 DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. *Int J Oncol* 29:713-719

32. **Poma P, Notarbartolo M, Labbozzetta M, Sanguedolce R, Alaimo A, Carina V, Maurici A, Cusimano A, Cervello M, D'Alessandro N** 2006 Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. *Int J Oncol* 28:923-930
33. **Tatetsu H, Okuno Y, Nakamura M, Matsuno F, Sonoki T, Taniguchi I, Uneda S, Umezawa K, Mitsuya H, Hata H** 2005 Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner. *Mol Cancer Ther* 4:1114-1120
34. **Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, Yamamoto N, Umezawa K, Horie R** 2005 A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. *Int J Cancer* 114:32-38
35. **Watanabe M, Ohsugi T, Shoda M, Ishida T, Aizawa S, Maruyama-Nagai M, Utsunomiya A, Koga S, Yamada Y, Kamihira S, Okayama A, Kikuchi H, Uozumi K, Yamaguchi K, Higashihara M, Umezawa K, Watanabe T, Horie R** 2005 Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. *Blood* 106:2462-2471
36. **Kimura N, Miyakawa Y, Kohmura K, Umezawa K, Ikeda Y, Kizaki M** 2007 Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. *Leuk Res* 31:1529-1535
37. **Hunter AM, LaCasse EC, Korneluk RG** 2007 The inhibitors of apoptosis (IAPs) as cancer targets. *Apoptosis* 12:1543-1568
38. **Sato A, Oya M, Ito K, Mizuno R, Horiguchi Y, Umezawa K, Hayakawa M, Murai M** 2006 Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. *Int J Oncol* 28:841-846

39. **Oyaizu H, Adachi Y, Okumura T, Okigaki M, Oyaizu N, Taketani S, Ikebukuro K, Fukuhara S, Ikehara S** 2001 Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. *Oncol Rep* 8:825-829
40. **Ruan HY, Masuda M, Ito A, Umezawa K, Nakashima T, Yasumatsu R, Kuratomi Y, Yamamoto T, Weinstein IB, Komune S** 2006 Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. *Head Neck* 28:158-165
41. **Horie R, Watanabe M, Okamura T, Taira M, Shoda M, Motoji T, Utsunomiya A, Watanabe T, Higashihara M, Umezawa K** 2006 DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. *Leukemia* 20:800-806
42. **Jazirehi AR, Vega MI, Bonavida B** 2007 Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. *Cancer Res* 67:1270-1281
43. **Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, Watanabe T, Umezawa K, Urano T** 2005 In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. *Carcinogenesis* 26:1382-1388
44. **Ohsugi T, Kumasaka T, Okada S, Ishida T, Yamaguchi K, Horie R, Watanabe T, Umezawa K** 2007 Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines. *Cancer Lett* 257:206-215
45. **Ohsugi T, Kumasaka T, Ishida A, Ishida T, Horie R, Watanabe T, Umezawa K, Yamaguchi K** 2006 In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. *Leuk Res* 30:90-97
46. **Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M** 2005 Prevention of cancer cachexia by a novel

- nuclear factor {kappa}B inhibitor in prostate cancer. Clin Cancer Res 11:5590-5594
47. **Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M** 2003 Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res 63:107-110

Figure legends

Fig. 1

Cytotoxic effect of taxanes and/or DHMEQ on anaplastic thyroid cancer cells

Viabilities of FRO and ARO cells exposed to indicated concentrations of docetaxel, paclitaxel, and/or DHMEQ for 24 hours were determined by WST assay as described in *Materials and Methods*. Bars represent the mean \pm SD of four wells. Similar results were obtained in at least three independent experiments.

Fig. 2

Combined effects were also observed in cells with wt-p53 or in cells treated with SN50

Viability of indicated cells exposed to 4 nM docetaxel and/or 10 μ g/ml DHMEQ or 50 μ g/ml SN50 for 24 hours were determined by WST assay as described in *Materials and Methods*. Bars represent the mean and SD of four wells. Similar results were obtained in at least three independent experiments. * p <0.05 vs other groups.

Fig. 3

Taxanes induce NF- κ B activation, and DHMEQ inhibits the effect

A, DNA-binding assay. FRO cells were preincubated with or without 10 μ g/ml DHMEQ for 1 hour and then treated with 4 nM docetaxel for 24 hours. Nuclear extracts were prepared, and DNA-binding assay were done as described in *Materials and Methods*. Bars represent the mean \pm SD of three wells. Similar results were obtained in three independent experiments. B, Western blotting. FRO cells were treated with 4 nM docetaxel and/or 10 μ g/ml DHMEQ for indicated times, and then total cell lysates (for I κ B α) or nuclear protein extracts (for p50 and p65) were examined using indicated primary antibodies. Similar results were obtained in three independent experiments. C, Western blotting. Indicated cells were treated with 4 nM taxanes and/or 10 μ g/ml DHMEQ for 4 hours, and then nuclear protein extracts were examined for indicated subunit of NF- κ B by Western blotting. Similar results were obtained in three independent experiments.

Fig. 4

Effect of taxanes and DHMEQ on PARP cleavage and caspase 3 activation

A and B, Indicated cells were treated with the indicated drugs for 24 hours (4 nM taxanes and/or 10 µg/ml DHMEQ), and whole cell lysates were examined by Western blotting for PARP (A) and caspase 3 (B). C, FRO cells were preincubated with or without 10 µg/ml DHMEQ for 1 hour, and then treated with 4 nM docetaxel for the indicated times. Whole cell lysates were examined by Western blotting for PARP and caspase 3. A, B and C, β-actin was used as a loading control. Similar results were obtained in at least three independent experiments.

Fig. 5

Apoptotic changes in cells treated with drugs

Five groups of FRO cells with different treatments (4 nM docetaxel, 10 µg/ml DHMEQ, docetaxel plus DHMEQ, 10 J/m² of ultraviolet, and control with DMSO only) for 16 hours were harvested by trypsinization and subjected to annexin V/propidium iodide apoptosis detection assay using a FACS Vantage SE flow cytometer. FITC and propidium iodide emissions were detected in the FL-1 and FL-3 channels, respectively. Percentage of annexin V-positive cells (on the right) represents the sums of upper right and lower right quadrants, and percentage of propidium iodide-positive cells (on the top) represents the sums of top left and top right quadrants. Similar results were obtained in two independent experiments.

Fig. 6

Effect of taxanes and DHMEQ on anti-apoptotic factors

Indicated cells were treated with 4 nM taxanes and/or 10 µg/ml DHMEQ for 24 hours and whole cell lysates were examined by Western blotting for XIAP (A) and survivin (B). β-actin was used as a loading control. Similar results were obtained in at least three independent experiments.

Fig. 7

Effect of docetaxel and DHMEQ in FRO tumor xenograft model

FRO cells (5×10^6) were implanted as described in *Materials and Methods*. DHMEQ was injected i.p. at a dose of 6 mg/kg/day for 14 days, beginning on day 5 after tumor implantation. Docetaxel was injected i.p. at a dose of 5 mg/kg on day 5 and day 12. Combined treatment mice were given both drugs. Control group mice received vehicle injections only. In control groups, tumors did not appear at three locations (in two mice) until day 32. Data are presented as the mean \pm SD of 12 tumors (in 6 mice). * $p < 0.05$ vs any other group.

Fig. 8

Proposed mechanism of combined treatment

In ATC cells, taxanes bind to microtubule, impair mitosis, and induce apoptosis, yet, at the same time, they also induce NF- κ B activation, leading to dampening taxanes effect. DHMEQ blocks taxanes-induced NF- κ B activation, and together with its own cell-killing effect, cancer cell apoptosis is greatly enhanced.

Figure 1




Figure 2




Figure 3






Figure 4




Figure 5




Figure 6





Figure 7




Figure 8

